Compensated Advanced Chronic Liver Disease and Steatosis in Patients with Type 2 Diabetes as Assessed through Shear Wave Measurements and Attenuation Measurements

Compensated Advanced Chronic Liver Disease and Steatosis in Patients with Type 2 Diabetes as Assessed through Shear Wave Measurements and Attenuation Measurements

Patients with type 2 diabetes (T2D) are at risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD). We investigated the prevalence of compensated advanced chronic liver disease (cACLD) and steatosis in patients with T2D using the new non-invasive diagnostic methods of she...

Full description

Bibliographic Details
Main Authors:	Mislav Barisic-Jaman, Marko Milosevic, Viktoria Skurla, David Dohoczky, Josip Stojic, Petra Dinjar Kujundzic, Maja Cigrovski Berkovic, Ana Majic-Tengg, Ana Matijaca, Tomo Lucijanic, Mirjana Kardum-Pejic, Vlatka Pandzic Jaksic, Srecko Marusic, Ivica Grgurevic
Format:	Article
Language:	English
Published:	MDPI AG 2024-01-01
Series:	Biomedicines
Subjects:	MASLD diabetes mellitus ultrasound elastography liver fibrosis liver steatosis
Online Access:	https://www.mdpi.com/2227-9059/12/2/323

Similar Items

Navigating the Nomenclature of Liver Steatosis: Transitioning from NAFLD to MAFLD and MASLD - Understanding Affinities and Differences
by: Apichat Kaewdech, et al.
Published: (2024-04-01)

Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients
by: David Pérez Compte, et al.
Published: (2024-04-01)

Improved Applicability and Diagnostic Accuracy of the Novel Spleen-Dedicated Transient Elastography Device for High-Risk Esophageal Varices
by: Anita Madir, et al.
Published: (2024-03-01)

Liver Elastography for Liver Fibrosis Stratification: A Comparison of Three Techniques in a Biopsy-Controlled MASLD Cohort
by: Antonio Liguori, et al.
Published: (2025-01-01)

Advanced liver fibrosis, but not MASLD, is associated with accelerated biological aging: a population-based study
by: Chengcheng Tong, et al.
Published: (2024-11-01)

Prevalence of metabolic dysfunction-associated steatotic liver disease and steatohepatitis in Türkiye: A forensic autopsy study
by: Ilkay Ergenc, et al.
Published: (2024-08-01)

Editorial: Inflammatory responses on the road from NASH to HCC: pathogenic mechanisms and possible therapeutic strategies
by: Veronika Lukacs-Kornek, et al.
Published: (2024-11-01)

An Assessment of the Feasibility, Patient Acceptance, and Performance of Point-of-Care Transient Elastography for Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis
by: Taranika Sarkar Das, et al.
Published: (2024-11-01)

The combined pioglitazone and topiramate therapy for management of pediatric patients with severe MASLD
by: Callen Conroy, et al.
Published: (2024-08-01)

Glucagon, Metabolic Dysfunction-Associated Steatotic Liver Disease and Amino Acids in Humans and Animals without Diabetes Mellitus—An Evidence Map
by: Katharina Maruszczak, et al.
Published: (2024-10-01)

Grading of Fatty Liver Based on Computed Tomography Hounsfield Unit Values versus Ultrasonography Grading
by: Sultan Abdulwadoud Alshoabi, et al.
Published: (2024-07-01)

Machine Learning for Short-Term Mortality in Acute Decompensation of Liver Cirrhosis: Better than MELD Score
by: Nermin Salkić, et al.
Published: (2024-05-01)

The interaction of genetics and physical activity in the pathogenesis of metabolic dysfunction associated liver disease
by: Hanna Frostdahl, et al.
Published: (2024-08-01)

Nicotinamide Adenine Dinucleotide Phosphate Oxidases and Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Vittoria Cammisotto, et al.
Published: (2025-01-01)

The plasma lipidome varies with the severity of metabolic dysfunction-associated steatotic liver disease
by: Clément J. F. Heymann, et al.
Published: (2024-12-01)

Statin Use in Metabolic Dysfunction-Associated Steatotic Liver Disease and Effects on Vibration-Controlled Transient Elastography-Derived Scores—A Population-Based Inverse Probability Treatment Weighting Analysis
by: Natchaya Polpichai, et al.
Published: (2024-12-01)

GCKIII kinases control hepatocellular lipid homeostasis via shared mode of action
by: Emmelie Cansby, et al.
Published: (2024-11-01)

Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality
by: Donghee Kim, et al.
Published: (2024-10-01)

Intra and inter-organ communication through extracellular vesicles in obesity: functional role of obesesomes and steatosomes
by: N. Lago-Baameiro, et al.
Published: (2025-02-01)

Therapeutic Actions of Hepatocyte Extracellular Vesicles in a Murine Model of Diet-Induced Steatohepatitis with Fibrosis
by: Xinlei Li, et al.
Published: (2025-01-01)

Associations of five dietary indices with metabolic dysfunction-associated steatotic liver disease and liver fibrosis among the United States population
by: Min Xu, et al.
Published: (2024-08-01)

Gut Microbiome and Hepatic Transcriptomic Determinants of HCC Development in Mice with Metabolic Dysfunction-Associated Steatohepatitis
by: Dolapchiev LI, et al.
Published: (2024-10-01)

Glucagon-like Peptide-1 Receptor Agonists—A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Erika Choi, et al.
Published: (2024-02-01)

Adding to the confusion in more than just the name
by: Jacob George
Published: (2023-10-01)

The Interplay between Liver and Adipose Tissue in the Onset of Liver Diseases: Exploring the Role of Vitamin Deficiency
by: Ivan Tattoli, et al.
Published: (2024-09-01)

Editorial: Community series - liver fibrosis and MAFLD: from molecular aspects to novel pharmacological strategies, volume II
by: Ana Sandoval-Rodriguez, et al.
Published: (2024-02-01)

Successful Example of Implementing Screening of Liver Fibrosis in Specialist Diabetes Care
by: Muna Tajudin, et al.
Published: (2025-01-01)

Exploring the Role of Peroxisome Proliferator-Activated Receptors and Endothelial Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Ana Paula Madariaga Traconis, et al.
Published: (2024-12-01)

Non-invasive testing in metabolic dysfunction-associated steatotic liver disease
by: Sanad Dawod, et al.
Published: (2024-11-01)

Steatotic liver disease in people with HIV at Tshepong Hospital: A post-mortem analysis
by: Aqeela Moosa, et al.
Published: (2024-12-01)

Golgi protein 73: charting new territories in diagnosing significant fibrosis in MASLD: a prospective cross-sectional study
by: Shan Hong, et al.
Published: (2025-01-01)

Lean MASLD and IBD: Exploring the Intersection of Metabolic Dysfunction and the Gut–Liver Axis
by: Adrian Rotaru, et al.
Published: (2025-02-01)

Clopidogrel ameliorates high-fat diet-induced hepatic steatosis in mice through activation of the AMPK signaling pathway and beyond
by: Ting Tai, et al.
Published: (2024-10-01)

Metabolic-associated steatotic liver disease and risk of Alzheimer’s disease: a real-world retrospective cohort study
by: Jiaqi Zhang, et al.
Published: (2024-09-01)

Association of MAFLD and MASLD with all-cause and cause-specific dementia: a prospective cohort study
by: Xue Bao, et al.
Published: (2024-06-01)

Iron, Oxidative Stress, and Metabolic Dysfunction—Associated Steatotic Liver Disease
by: Sophie Gensluckner, et al.
Published: (2024-02-01)

Response to Article “Effect of Helicobacter Pylori Infection on Glucose Metabolism, Lipid Metabolism and Inflammatory Cytokines in Nonalcoholic Fatty Liver Disease Patients” [Letter]
by: Yuliandari P, et al.
Published: (2024-03-01)

Innate Immunity and MASLD
by: Moritz Meyer, et al.
Published: (2024-04-01)

Economic Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italy. Analysis and Perspectives
by: Torre E, et al.
Published: (2024-10-01)

Immunotherapy and MASLD-Related HCC: Should We Reconsider the Role of Etiology in the Therapeutic Approach to HCC?
by: Giuseppina Vizioli, et al.
Published: (2025-02-01)